ISO 13485 & 9001 certified
Residual DNA and HCP kits, microbial and process-residual assays, and GMP reagents for mRNA synthesis: the features that set each product apart, one table per family.
Choose by expression system: CHO, HEK293, human, E. coli, Sf9 with AcNPV (both targets in one well) or plasmid DNA. Among the kits reported in fg/µL, the CHO kit BP-QN88-100 has the lowest stated LOQ, 0.5 fg/µL.
| Product | Target DNA | Calibrator range | Validated LOQ / LOD | Two targets in one well | Fluorescence channels / ABI reference | DNA input per reaction |
|---|---|---|---|---|---|---|
| CHO residual DNABP-QN88-100 | CHO genomic DNA | 3 fg/µL–300 pg/µL (6 levels) | LOQ 0.5 fg/µL; LOD 0.125 fg/µL | ✕No | FAM (CHO DNA) / CY5 (IC); ROX reference on ABI | 10 µL DNA + 20 µL MIX (30 µL) |
| HEK293 residual DNABP-QN09-100 | HEK293 genomic DNA | 30 fg/µL–300 pg/µL (5 levels) | LOQ 10 fg/µL | ✕No | FAM (HEK293 DNA) / ROX (IC); reference = none on ABI | 20 µL DNA + 20 µL MIX (40 µL) |
| Human residual DNABP-QN54-100 | Human genomic DNA | 30 fg/µL–300 pg/µL (5 levels) | LOQ 10 fg/µL | ✕No | FAM (human DNA) / ROX (IC); reference = none on ABI | 20 µL DNA + 20 µL MIX (40 µL) |
| E. coli residual DNABP-QN24-100 | E. coli genomic DNA | 30 fg/µL–300 pg/µL (5 levels) | LOQ 5 fg/µL; LOD 1 fg/µL | ✕No | FAM (E. coli DNA) / ROX (IC); reference = none on ABI | 20 µL DNA + 20 µL MIX (40 µL) |
| Sf9 & AcNPV residual DNABP-QN21-100 | Sf9 genomic DNA + AcNPV DNA | Sf9 3 fg/µL–300 pg/µL; AcNPV 3–3×10⁵ copies/µL (6 levels) | Sf9: LOQ 1.5 fg/µL, LOD 0.2 fg/µL; AcNPV: LOQ 3 copies/µL, LOD 0.3 copies/µL | YesSf9 + AcNPV | FAM (Sf9) / ROX (AcNPV) / CY5 (IC); reference = none on ABI | 20 µL DNA + 20 µL MIX (40 µL) |
| Plasmid DNA residueBP-QN120-100 | Plasmid DNA (consensus plasmid sequences) | 5×10¹–5×10⁶ copies/µL (6 levels) | LOQ 10 copies/µL | ✕No | FAM (plasmid DNA) / CY5 (IC); ROX reference on ABI | 10 µL DNA + 20 µL MIX (30 µL) |
Choose by host: CHO, HEK293 or MDCK, or E. coli, with separate kits for expression strains (BL21, W3110) and cloning strains (DH5α, Top10, JM109, Stbl3). The CHO, MDCK and both E. coli kits are validated per USP, EP and ChP.
| Product | Host cell lines / strains covered | Assay range | LOD / LOQ | Calibrator format | No cross-reactivity shown with | Validated per USP / EP / ChP |
|---|---|---|---|---|---|---|
| CHO HCP ELISABP-QP-C035 | CHO-K1, CHO-DG44, CHOZN | 1.56–100 ng/mL | LOD ~0.5 ng/mL; LOQ ~1 ng/mL | Ready-to-use, 8 levels | P. pastoris, MDCK, Sf9, HEK293, E. coli | Yes |
| HEK293 HCP ELISABP-QP-H005 | HEK293, HEK293F, HEK293T | 4–200 ng/mL | LOD 2 ng/mL | Single concentrated stock; user serial dilution | –Not applicable or no data | ✕No |
| MDCK HCP ELISABP-QP-M006 | MDCK | 3–200 ng/mL | LOQ 3 ng/mL | Ready-to-use, 8 levels | CHO, HEK293 | Yes |
| E. coli expression-strain HCP ELISABP-QP-E032 | BL21, W3110 | 2–100 ng/mL | LOD ~0.577 ng/mL; LOQ ~1.55 ng/mL | Lyophilized; reconstitute, then serial dilution | P. pastoris, MDCK, Sf9, HEK293, CHO | Yes |
| E. coli cloning-strain HCP ELISABP-QP-E030 | DH5α, Top10, JM109, Stbl3 | 1–243 ng/mL | LOD ~0.25 ng/mL; LOQ ~0.82 ng/mL | Lyophilized; reconstitute, then serial dilution | P. pastoris, MDCK, Sf9, HEK293, CHO | Yes |
One kit per contamination risk. The mycoplasma, mycobacteria, spiroplasma, bacteria and fungi kits give qualitative results; the RCL kit BP-QN10-100 quantifies replication-competent lentivirus by VSV-G copy number.
| Product | Target (gene region) | Result type | Limit of detection | Strains verified / coverage | Internal control | Fluorescence channels / ABI reference |
|---|---|---|---|---|---|---|
| Mycoplasma DNABP-QN22-50 | Mycoplasma (16S rRNA) | Qualitative | 5 CFU/mL (in a 10⁶ cells/mL matrix) | 10 strains at LOD (incl. EP 2.6.7 species); >200 species in silico | Exogenous IC (add at extraction or PCR) | FAM (target) / VIC (IC); ROX reference on ABI |
| Mycobacterium DNABP-QN15-50 | Mycobacterium (conserved genomic region) | Qualitative | 10 CFU | 12 strains at LOD | Exogenous IC (add at extraction or PCR) | FAM (target) / ROX (IC); reference = none on ABI |
| Spiroplasma DNABP-QN299-50 | Spiroplasma (16S rRNA) | Qualitative | 10 CFU/mL | 1 pharmacopoeia-specified strain (S. citri) at LOD; >40 species in silico | Exogenous IC (add at extraction or PCR) | FAM (target) / VIC (IC); ROX reference on ABI |
| Bacteria DNABP-QN99-50 | Bacteria (16S rRNA) | Qualitative | 10 CFU/reaction | 9 strains at 100 CFU; ~92% of 16S sequences in silico | Exogenous IC (add at extraction or PCR) | FAM (target) / Cy5 (IC); ROX reference on ABI |
| Fungi DNABP-QN78-50 | Fungi (18S rRNA) | Qualitative | 10 CFU/reaction | 2 strains at 100 CFU; ~92% of 18S sequences in silico | Exogenous IC (add at extraction or PCR) | FAM (target) / Cy5 (IC); ROX reference on ABI |
| RCL copy numberBP-QN10-100 | RCL (VSV-G gene) | Quantitative (copies/µL) | 0.15 copies/µL | –Not applicable or no data | Endogenous single-copy human gene (no value in non-human samples) | FAM (target) / ROX (IC); reference = none on ABI |
The ELISA kits measure residual protein mass of T7 RNA polymerase, RNase inhibitor and DNase I, plus dsRNA. The fluorogenic kits measure residual DNase BP-16 or RNase BP-06-100 activity by kinetic fluorescence, read every 5 minutes for at least 6 readings.
| Product | Analyte | Result reported as | Method & readout | Standard-curve range | LOD / LOQ | Incubation / read time |
|---|---|---|---|---|---|---|
| T7 RNA polymerase ELISABP-QP-T009-96 | T7 RNA polymerase | Protein mass (ng/mL) | Sandwich ELISA, OD450/630 | 1–64 ng/mL | LOD 0.1 ng/mL | ≈70 min (60 + 10 min) |
| RNase inhibitor ELISABP-QP-R014-96 | RNase inhibitor | Protein mass (ng/mL) | Sandwich ELISA, OD450/630 | 0.23–57 ng/mL | LOQ 0.23 ng/mL | ≈135 min (120 + 15 min) |
| DNase I ELISABP-QP-D013-96 | DNase I | Protein mass (ng/mL) | Sandwich ELISA, OD450/630 | 1–64 ng/mL | LOQ 0.1 ng/mL | ≈80 min (60 + 20 min) |
| dsRNA ELISA 2.0BP-18-96 | dsRNA | dsRNA mass (ng/mL) | Sandwich ELISA, OD450 (OD450/630 recommended) | 0.047–3 ng/mL (UTP, pUTP); 0.093–6 ng/mL (N1-Me-pUTP) | –Not applicable or no data | ≈145 min (60 + 60 + 25 min) |
| Residual DNase activityBP-16 | DNase | Activity, DNase I-equivalent (U) | Fluorogenic probe, kinetic fluorescence (Ex/Em 530/560 nm, 37 °C) | 0.000025–0.0016 U DNase I | LOD 1.25×10⁻⁵ U DNase | ≥6 reads at 5-min intervals (≈25 min) |
| Residual RNase activityBP-06-100 | RNase (RNase A-type) | Activity, RNase A-equivalent (pg) | Fluorogenic probe, kinetic fluorescence (Ex/Em 490/520 nm, 37 °C) | 0.078–10 pg RNase A | LOD 0.078 pg RNase | ≥6 reads at 5-min intervals (≈25 min) |
For GMP production choose a T7 enzyme: T7 3.0 GMP-BP-E11 gives 7–8-fold less dsRNA than wild-type T7. The research kits make linear RNA BP-01-50, co-transcriptionally capped Cap1 mRNA with N1-Me-pUTP supplied (BP-07-50; the template needs an AG initiation sequence) or circRNA BP-13-50.
| Product | Format | GMP grade | RNA product | 5′ capping | Low-dsRNA T7 variant | N1-Me-pUTP supplied | Template requirement | Yield per 20 µL reaction |
|---|---|---|---|---|---|---|---|---|
| T7 RNA Polymerase, GMPGMP-BP-E01 | Enzyme only (50 U/µL) | Yes | Linear RNA | Not included: add cap analog or cap enzymatically after IVT | ✕No | ✕No | T7 promoter (5′-TAATACGACTCACTATAG-3′) | >200 µg |
| T7 RNA Polymerase 3.0 low dsRNA, GMPGMP-BP-E11 | Enzyme only (50 U/µL) | Yes | Linear RNA | Not included: add cap analog or cap enzymatically after IVT | Yes7–8-fold less dsRNA vs wild-type T7 | ✕No | T7 promoter (5′-TAATACGACTCACTATAG-3′) | >200 µg |
| T7 High-Efficiency Transcription KitBP-01-50 | Complete kit | ✕No | Linear RNA | Not included: add cap analog or cap enzymatically after IVT | ✕No | ✕No | Linearized plasmid or PCR product with T7 promoter | >200 µg from 1 µg template |
| mRNA Co-transcription Kit, Cap1BP-07-50 | Complete kit | ✕No | Cap1 mRNA (co-transcriptional) | Co-transcriptional, cap analog supplied (Cap AG(3'Acm)) | ✕No | Yes | Linearized plasmid or PCR product with T7 promoter + AG initiation sequence | 150–200 µg Cap1 RNA from 1 µg template |
| CircRNA Synthesis KitBP-13-50 | Complete kit | ✕No | circRNA (Group I intron self-splicing) | Not applicable (circRNA) | ✕No | ✕No | Linearized plasmid or PCR product with T7 promoter | >150 µg |
Vaccinia Capping Enzyme GMP-BP-E05 makes Cap0; Cap 2′-O-Methyltransferase GMP-BP-E06 converts Cap0 to Cap1. The mRNA Capping Kit BP-04-50 does both in one tube, with a stated Cap1 efficiency of ≥95%. To cap during IVT instead, see the co-transcription kit above.
| Product | Cap structure produced | GMP grade | Enzyme concentration | Co-supplied reagents | Stated capping efficiency |
|---|---|---|---|---|---|
| Vaccinia Capping Enzyme, GMPGMP-BP-E05 | Cap0 (from uncapped RNA) | Yes | 10 U/µL | 10× capping buffer, GTP, SAM | Up to 100% (Cap0) |
| Cap 2′-O-Methyltransferase, GMPGMP-BP-E06 | Cap1 (methylates Cap0 RNA) | Yes | 50 U/µL | 10× capping buffer, SAM | Up to 100% (Cap1) |
| mRNA Capping Kit, Cap1BP-04-50 | Cap1 in one tube (VCE + 2′-O-MTase, from uncapped RNA) | ✕No | VCE 10 U/µL; 2′-O-MTase 10 U/µL | 10× capping buffer, GTP, SAM, RNase inhibitor | ≥95% (Cap1) |
BsaI GMP-BP-E10 and BspQI GMP-BP-E09 cut outside their recognition sites; EcoRI GMP-BP-E16 cuts within it. BspQI digests at 50 °C, BsaI and EcoRI at 37 °C.
| Product | Recognition / cleavage site | Cuts outside recognition site | Concentration | Digestion conditions | Heat inactivation |
|---|---|---|---|---|---|
| BsaI, GMPGMP-BP-E10 | GGTCTC(N1/N4) | Yes | 20 U/µL | 37 °C, 1 h | 80 °C, 25 min |
| BspQI, GMPGMP-BP-E09 | GCTCTTC(N1/N4) | Yes | 10 U/µL | 50 °C, 1 h | 80 °C, 20 min |
| EcoRI, GMPGMP-BP-E16 | G↓AATTC | ✕No | >20 U/µL | 37 °C, 1 h | 65 °C, 20 min |
All six are 100 mM ± 3 mM and ≥99% pure by HPLC. For modified mRNA, replace UTP with pseudo-UTP GMP-BP-AS-05 or N1-Me-pUTP GMP-BP-AS-07.
| Product | Nucleoside modification | Replaces in IVT | Concentration | Purity (HPLC) |
|---|---|---|---|---|
| ATP, GMPGMP-BP-AS-01 | None (natural) | –Not applicable or no data | 100 mM ± 3 mM | ≥99% (HPLC) |
| GTP, GMPGMP-BP-AS-02 | None (natural) | –Not applicable or no data | 100 mM ± 3 mM | ≥99% (HPLC) |
| CTP, GMPGMP-BP-AS-03 | None (natural) | –Not applicable or no data | 100 mM ± 3 mM | ≥99% (HPLC) |
| UTP, GMPGMP-BP-AS-04 | None (natural) | –Not applicable or no data | 100 mM ± 3 mM | ≥99% (HPLC) |
| Pseudo-UTP, GMPGMP-BP-AS-05 | Pseudouridine (Ψ) | UTP | 100 mM ± 3 mM | ≥99% (HPLC) |
| N1-Me-pUTP, GMPGMP-BP-AS-07 | N1-methylpseudouridine (m1Ψ) | UTP | 100 mM ± 3 mM | ≥99% (HPLC) |
Features are based on each product’s instruction manual, product page and data from our technical team. Prices, pack sizes and full specifications are on the product pages. Not every product is listed here; see the full range in Biopharma.
Selection guides for our other product lines.
Send your application, sample type and key requirements. We reply within one business day with a recommendation and sample options.
Not ready for a quote? Discuss feasibility, formats, host systems or validation with the specialist behind this page — no sales script.
Topic detected: your enquiryReply within one business day from an application scientist. For pricing, COA or samples, use Request a quote instead.
Four fields. We route it to the right person and reply the way you prefer.
🔒 Used only to reply to this request. No newsletters. Privacy Policy
Need pricing, a COA or samples? Request a quote →
* Your data is securely protected for essential communications only. We won’t share your details or send spam emails, Privacy Policy *
